Is there a role for nuclear factor κB in tumor necrosis factor-related apoptosis-inducing ligand resistance?

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 38-49

  Plantivaux, Amandine ^a   Szegezdi, Eva ^a   Samali, Afshin ^a   Egan, Laurence ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Apoptosis; Cancer; MTOR; NF B; Proteasome inhibitors; Resistance; Super repressor; TRAIL

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER CELL CULTURE; CONFERENCE PAPER; DRUG RESISTANCE; ENZYME INHIBITION; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL CULTURE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 69149108568     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04725.x     Document Type: Conference Paper

References (70)

1. Wiley, S.R. et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 : 673 682.
2. Pitti, R.M. et al. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271 : 12687 12690.
3. Fesik, S.W. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5 : 876 885.
4. Merino, D. et al. 2007. TRAIL in cancer therapy: present and future challenges. Expert Opin. Ther. Targets 11 : 1299 1314.
5. Lee, J.Y. et al. 2007. The NO TRAIL to YES TRAIL in cancer therapy (review). Int. J. Oncol. 31 : 685 691.
6. Hall, M.A. J.L. Cleveland. 2007. Clearing the TRAIL for cancer therapy. Cancer Cell 12 : 4 6.
7. Suliman, A. et al. 2001. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 20 : 2122 2133.
8. Koschny, R., H. Walczak T.M. Ganten. 2007. The promise of TRAIL-potential and risks of a novel anticancer therapy. J. Mol. Med. 85 : 923 935.
9. Ehrhardt, H. et al. 2003. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22 : 3842 3852.
10. Grotzer, M.A. et al. 2000. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19 : 4604 4610.
11. Vasilevskaya, I.A. P.J. O'Dwyer. 2005. 17-Allylamino-17- demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem. Pharmacol. 70 : 580 589.
12. Jin, Z. et al. 2004. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 279 : 35829 35839.
13. Sheridan, J.P. et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 : 818 821.
14. Marsters, S.A. et al. 1997. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7 : 1003 1006.
15. Finnberg, N. W.S. El-Deiry. 2006. Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies. Clin. Cancer Res. 12 : 4132 4136.
16. Sen, R. D. Baltimore. 1986. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46 : 705 716.
17. Sullivan, J.C. et al. 2007. Rel homology domain-containing transcription factors in the cnidarian Nematostella vectensis. Dev. Genes Evol. 217 : 63 72.
18. Zandi, E. et al. 1997. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91 : 243 252.
19. Dolcet, X. et al. 2005. NF-kB in development and progression of human cancer. Virchows Arch. 446 : 475 482.
20. Karin, M. 2006. Nuclear factor-kappaB in cancer development and progression. Nature 441 : 431 436.
21. Aranha, M.M. et al. 2007. NF-kappaB and apoptosis in colorectal tumourigenesis. Eur. J. Clin. Invest. 37 : 416 424.
22. Egan, L.J. M. Toruner. 2006. NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach. Ann. N. Y. Acad. Sci. 1072 : 114 122.
23. Cusack, J.C., Jr., R. Liu A.S. Baldwin, Jr. 2000. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]- carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res. 60 : 2323 2330.
24. Russo, S.M. et al. 2001. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int. J. Radiat. Oncol. Biol. Phys. 50 : 183 193.
25. Beg, A.A. D. Baltimore. 1996. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274 : 782 784.
26. Schneider, P. et al. 1997. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7 : 831 836.
27. Varfolomeev, E. et al. 2005. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem. 280 : 40599 40608.
28. Jin, Z. W.S. El-Deiry. 2006. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol. Cell Biol. 26 : 8136 8148.
29. Ravi, R. et al. 2006. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res. 66 : 1730 1739.
30. Zwacka, R.M., L. Stark M.G. Dunlop. 2000. NF-kappaB kinetics predetermine TNF-alpha sensitivity of colorectal cancer cells. J. Gene Med. 2 : 334 343.
31. Adams, J. 2004. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5 : 417 421.
32. Nagy, K. et al. 2006. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Pathol. Oncol. Res. 12 : 133 142.
33. Franco, A.V. et al. 2001. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J. Immunol. 166 : 5337 5345.
34. Mitsiades, C.S. et al. 2001. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98 : 795 804.
35. Roff, M. et al. 1996. Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J. Biol. Chem. 271 : 7844 7850.
36. Brooks, A.D. et al. 2005. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann. N. Y. Acad. Sci. 1059 : 160 167.
37. An, J. et al. 2004. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18 : 1699 1704.
38. Hideshima, T. et al. 2002. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 277 : 16639 16647.
39. Zhang, H.G. et al. 2004. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23 : 2009 2015.
40. Romagnoli, M. et al. 2007. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin. Cancer Res. 13 : 6010 6018.
41. DiDonato, J. et al. 1996. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell Biol. 16 : 1295 1304.
42. Jeremias, I. et al. 1998. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 91 : 4624 4631.
43. Keane, M.M. et al. 2000. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res. Treat. 64 : 211 219.
44. Braeuer, S.J. et al. 2006. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol. Cancer Res. 4 : 715 728.
45. Harper, N. et al. 2001. Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases. J. Biol. Chem. 276 : 34743 34752.
46. Williams, A.C. et al. 2007. Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ. 14 : 137 145.
47. Ricci, M.S. et al. 2007. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12 : 66 80.
48. Khanbolooki, S. et al. 2006. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 5 : 2251 2260.
49. Kurbanov, B.M. et al. 2007. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 26 : 3364 3377.
50. Sayers, T.J. et al. 2003. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102 : 303 310.
51. Hu, W.H., H. Johnson H.B. Shu. 1999. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J. Biol. Chem. 274 : 30603 30610.
52. Pawlowski, J.E. et al. 2000. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL). Anticancer Res. 20 : 4243 4255.
53. Ishimura, N. et al. 2006. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 290 : G129 136.
54. Diessenbacher, P. et al. 2008. NF-κB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. J. Invest. Dermatol. 128 : 1134 1147.
55. Chaudhary, P.M. et al. 1997. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7 : 821 830.
56. Degli-Esposti, M.A. et al. 1997. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7 : 813 820.
57. Wagner, K.W. et al. 2007. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13 : 1070 1077.
58. Senftleben, U. et al. 2001. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293 : 1495 1499.
59. Schoonbroodt, S. et al. 2000. Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B activation by an oxidative stress. J. Immunol. 164 : 4292 4300.
60. Grosse-Wilde, A. et al. 2008. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest. 118 : 100 110.
61. Hague, A. et al. 2005. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br. J. Cancer 92 : 736 742.
62. Luo, J.L. et al. 2004. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6 : 297 305.
63. Hu, H. et al. 2006. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol. Cancer Ther. 5 : 1873 1882.
64. Perez-Cruz, I., J.M. Carcamo D.W. Golde. 2007. Caspase-8 dependent trail-induced apoptosis in cancer cell lines is inhibited by vitamin C and catalase. Apoptosis 12 : 225 234.
65. Hanna, S.C., S.A. Heathcote W.Y. Kim. 2008. mTOR pathway in renal cell carcinoma. Expert Rev. Anticancer Ther. 8 : 283 292.
66. Lee, D.F. et al. 2007. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130 : 440 455.
67. Dan, H.C., M. Adli A.S. Baldwin. 2007. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res. 67 : 6263 6269.
68. Panner, A. et al. 2005. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell Biol. 25 : 8809 8823.
69. Panner, A., A.T. Parsa R.O. Pieper. 2006. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Expert Rev. Anticancer Ther. 6 : 1313 1322.
70. Wu, Y. B.P. Zhou. 2007. Kinases meet at TSC. Cell Res. 17 : 971 973.